The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Marilyn S AlbertCreighton H Phelps

Abstract

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.

References

Apr 6, 1999·Archives of Neurology·R C PetersenE Kokmen
Sep 19, 2003·Neuroimaging Clinics of North America·Kejal Kantarci, Clifford R Jack
Sep 25, 2003·Lancet Neurology·Kaj Blennow, Harald Hampel
Sep 27, 2003·Alzheimer Disease and Associated Disorders·Monika AtiyaRonald Killiany
Apr 6, 2004·Clinics in Geriatric Medicine·David A Bennett
Aug 25, 2004·Journal of Internal Medicine·R C Petersen
Feb 16, 2005·Archives of Neurology·Dennis J Selkoe
Jan 13, 2006·Archives of Neurology·William R MarkesberyDavid R Wekstein
May 10, 2006·Archives of Neurology·Ronald C PetersenEmre Kokmen
Jul 4, 2006·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Constantine G LyketsosUNKNOWN Task Force of American Association for Geriatric Psychiatry
Aug 18, 2006·Journal of Alzheimer's Disease : JAD·Gerard D Schellenberg
Mar 20, 2009·Annals of Neurology·Leslie M ShawUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jan 1, 2006·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·William Jagust
Jul 2, 2010·Nature Reviews. Drug Discovery·Harald HampelKaj Blennow
Oct 20, 2010·Neuron·Lars BertramRudolph E Tanzi
Apr 26, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Clifford R JackCreighton H Phelps

❮ Previous
Next ❯

Citations

Feb 14, 2014·Trends in Molecular Medicine·Robert PerneczkyAlexander Kurz
Aug 10, 2011·Archives of Neurology·Clifford R JackUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Apr 5, 2012·Archives of Neurology·Lawrence S Honig
Jul 18, 2012·Archives of Neurology·Holly D SoaresUNKNOWN Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project
Sep 17, 2011·Der Nervenarzt·R ZimmermannP Lewczuk
May 12, 2012·Der Nervenarzt·U FiedlerJ Benninghoff
Jan 12, 2012·Experimental Brain Research·Ryosuke TsutsumiYoshikazu Ugawa
May 30, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Javier ArbizuUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jan 27, 2012·Zeitschrift für Gerontologie und Geriatrie·M C Polidori, L Pientka
Oct 1, 2011·Acta Neuropathologica·Sriram VennetiJohn Q Trojanowski
Nov 22, 2011·Acta Neuropathologica·Elliott J MufsonStephen W Scheff
Apr 25, 2012·Acta Neuropathologica·Jon B ToledoJohn Q Trojanowski
Oct 9, 2013·Acta Neuropathologica·Clifford R JackVladimir Kepe
Oct 25, 2013·Acta Neuropathologica·William T HuJohn Q Trojanowski
Jun 28, 2011·Journal of Neurology·Daniela Galimberti, Elio Scarpini
Oct 17, 2012·Journal of Neurology·Samantha GalluzziUNKNOWN Translational Outpatient Memory Clinic Working Group
Feb 22, 2012·Journal of Neural Transmission·Kurt A Jellinger
Jan 21, 2012·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Alberto CostaCarlo Caltagirone
Jul 21, 2011·Neuropsychology Review·Alberto CostaGiovanni Augusto Carlesimo
May 9, 2012·Brain Imaging and Behavior·Julene K JohnsonUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Oct 17, 2012·Brain Imaging and Behavior·Kwangsik NhoUNKNOWN Alzheimer’s Disease Neuroimaging Initiative--ADNI
Nov 28, 2012·Brain Imaging and Behavior·Christian HabeckUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Jul 5, 2011·Current Neurology and Neuroscience Reports·Luis F Gonzalez-CuyarThomas J Montine
Jul 4, 2012·Current Neurology and Neuroscience Reports·Molly E Zimmerman, Mark S Aloia
Jul 10, 2012·Current Psychiatry Reports·Yonas E Geda
Dec 28, 2011·Molecular Neurobiology·Anders M Fjell, Kristine B Walhovd
Jun 19, 2013·Drugs & Aging·Stefan HolzerSteve Iliffe
Mar 7, 2013·Archives of Gerontology and Geriatrics·Min-Jeong KimDuk L Na
Jun 22, 2013·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Pan WangTianzi Jiang
Oct 26, 2013·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Eric D VidoniUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Oct 10, 2013·Revue neurologique·T LebouvierP Derkinderen
Jul 10, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Dallas P SeitzNaveed Siddiqui
Aug 21, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Albert C YangJong-Ling Fuh
Dec 17, 2011·Lancet Neurology·Reisa A Sperling, Keith A Johnson
Sep 10, 2013·Lancet Neurology·Stephanie Jb VosAnne M Fagan
Sep 20, 2011·International Psychogeriatrics·Mary Ganguli, Eric Rodriguez
Nov 19, 2011·International Psychogeriatrics·Karen Ritchie, Craig W Ritchie
Mar 23, 2012·International Psychogeriatrics·Roberto Alves Lourenço, Emylucy Martins De Paiva Paradela

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Aging Epidemiology

This feed focuses on epidemiology of aging and aging-related conditions, including Alzheimer’s disease, dementia, and age-associated cognitive impairment. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.